Anirban Basu, PhD

Director, Professor
Pharmaceutical Outcomes Research and Policy Program, University of Washington
Dept. of Health Services, School of Public Health
1959 NE Pacific St
Magnuson Health Sciences Center, Room H-664, PO Box 357630
Seattle, WA
USA 98195-7660


Biographical Sketch: Anirban Basu is the Stergachis Family Endowed Professor and Director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington with additional appointments in the Department of Health Services, the Department of Economics and the National Bureau of Economic Research. Anirban’s work sits at the intersection of microeconomics, statistics, and health policy. His research focuses on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research, with a special emphasis on studying heterogeneity in clinical and economic outcomes in order to establish the realized and potential values of individualized care. Anirban is as an associate editor for Observational Studies, and in the past of Health Economics and the Journal of Health Economics. He served on the Second Panel on Cost-effectiveness in Health and Medicine. He is a past recipient of the ISPOR Methodology Awards and the Bernie O’Brien New Investigator Award. He is an elected Fellow of the American Statistical Association. Anirban has a Bachelor’s degree from India, a Masters in Biostatistics from the UNC, Chapel Hill, and a PhD in Public Policy with a concentration in health economics from the University of Chicago

Papers:
1C-4 VALUE OF INFORMATION METHODS FOR OPTIMAL TIMING OF BIOMARKER COLLECTION 3G-5 HEALTHY, WEALTHY, AND WISE? EXPLORING OPTIMISM BIAS IN PARENT PREDICTIONS ABOUT A CHILD'S FUTURE HEALTH AND SOCIOECONOMIC EXPECTATIONS 4K-5 EVIDENCE THRESHOLDS AND UNCERTAINTY IN PRECISION MEDICINE: USING VALUE OF INFORMATION TO ASSESS CLINICALLY- VS GENOMICALLY-INDIVIDUALIZED CARE PANEL: RECOMMENDATIONS OF THE SECOND PANEL ON COST-EFFECTIVENESS IN HEALTH AND MEDICINE PATIENT PREFERENCES FOR GENOMICS-BASED INDIVIDUALIZED HEALTHCARE: DEVELOPMENT OF A DISCRETE CHOICE EXPERIMENT INSTRUMENT ON PRECISION MEDICINE HOW WELL WERE HEART FAILURE CLINICAL TRIAL ENDPOINTS SELECTED? EVIDENCE FROM A REVIEW OF CLINICALTRIALS.GOV AND OBSERVATIONAL STUDIES